08Jul 2022
Mesenchymal Stem Cell–derived Nanovesicles as a Credible Agent for Therapy of Pulmonary Hypertension

Mesenchymal Stem Cell–derived Nanovesicles as a Credible Agent for Therapy of Pulmonary Hypertension

The study examined the therapeutic efficacy of MSC-NVs in preclinical models of PH in vitro and in vivo. Intervention with MSC-NVs improved the core pathologies of monocrotaline-induced PH in rats. Intravenous administration of MSC-NVs resulted in significant uptake within hypertensive lungs, pulmonary artery lesions, and especially pulmonary artery smooth muscle cells (PASMCs). These data highlight the efficacy and advantages of MSC-NVs over MSC-EVs as a promising therapeutic strategy against PH.

  • #pulmonology

Like

Save

Share